Clifton R. LaDuane
Known title: CFO, Secretary & TreasurerCIK: 0001488774
Clifton R. LaDuane's purchase track record
How the stock did after each of Clifton R. LaDuane's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
10
of 10 since September 20, 2021
Stock higher 6 months later
30%
3 months: 40%
Median 6-month return
-12.9%
3 months: -0.7%
Beat the S&P 500
30%
median -22.0% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/17/2024 | ZVRA | $14K | +28.4% | +21.6% | +6.5% |
| 9/6/2023 | ZVRA | $5K | -0.6% | +25.5% | +14.3% |
| 5/18/2023 | ZVRA | $14K | -2.2% | -15.3% | +7.4% |
| 3/10/2023 | ZVRA | $7K | +33.7% | +27.4% | +15.4% |
| 1/13/2023 | ZVRA | $4K | +13.8% | -14.0% | +12.7% |
| 9/30/2022 | ZVRA | $6K | -26.4% | -11.9% | +14.6% |
| 5/18/2022 | ZVRA | $6K | +12.6% | -7.8% | +0.9% |
| 11/18/2021 | ZVRA | $4K | -32.0% | -38.4% | -17.1% |
| 9/29/2021 | ZVRA | $2K | -0.8% | -41.9% | +5.6% |
| 9/20/2021 | ZVRA | $8K | -4.7% | -42.0% | +2.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ZVRA | ▲ Buy | Option Exercise | 140,667 | $0 | 12/31/2025 | View on chart |
| ZVRA | ▼ Sell | Tax Withholding | 48,513 | $435K | 12/31/2025 | View on chart |
| ZVRA | ▼ Sell | Open Market | 11,000 | $86K | 2/13/2025 | View on chart |
| ZVRA | ▲ Buy | Option Exercise | 43,333 | — | 1/31/2025 | View on chart |
| ZVRA | ▲ Buy | Open Market | 2,000 | $14K | 7/17/2024 | View on chart |
| ZVRA | ▲ Buy | Open Market | 1,000 | $5K | 9/6/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 51 | $252 | 5/18/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 2,000 | $10K | 5/18/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 689 | $3K | 5/18/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 1,725 | $7K | 3/10/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 610 | $4K | 1/13/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 25 | $140 | 1/13/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 600 | $4K | 9/30/2022 | View on chart |
| ZVRA | ▲ Buy | Open Market | 400 | $2K | 9/30/2022 | View on chart |
| ZVRA | ▲ Buy | Open Market | 1,200 | $6K | 5/18/2022 | View on chart |
| ZVRA | ▲ Buy | Open Market | 510 | $4K | 11/18/2021 | View on chart |
| ZVRA | ▲ Buy | Open Market | 215 | $2K | 9/29/2021 | View on chart |
| ZVRA | ▲ Buy | Open Market | 935 | $8K | 9/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price
Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price. Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.